China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving Loan Facility of up to USD 100 million with HSBC, a leading global bank and financial services institution. This customized financing solution is designed to support the expansion of Insilico’s proprietary novel drug discovery pipeline and the enhancement of its end-to-end diversified AI platform, Pharma.AI.
Insilico Medicine’s Research Collaborations and Achievements
Insilico Medicine, established in the Hong Kong Science and Technology Park (HKSTP) in 2019, has built target discovery and platform application teams to strengthen research collaborations with top research institutes such as the University of Cambridge, the University of Hong Kong, the University of Zurich, and the University of Toronto. Leveraging its Pharma.AI platform, the company has nominated 19 preclinical candidates across a comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules, demonstrating its robust progress in drug development.- Flcube.com
